An Analysis of a Phase II study MK-2206 plus Erlotinib in NSCLC

Karen L. Reckamp, MD, co-director, Lung Cancer and Thoracic Oncology Program, associate professor, City of Hope, the results of a phase II study of the AKT inhibitor MK-2206 plus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) who progressed on erlotinib.

Karen L. Reckamp, MD, co-director, Lung Cancer and Thoracic Oncology Program, associate professor, City of Hope, discusses the results of a phase II study of the AKT inhibitor MK-2206 plus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) who progressed on erlotinib.

Clinical Pearls:

  • There were two cohorts on this study. The first cohort contained patients who were EGFR wild- type and had previously responded to EGFR TKI therapy for at least 12 weeks while the other cohort contained EGFR mutated patients who had responded to EGFR TKI therapy for at least 12 weeks.
  • An improvement in disease control rate was found in the first cohort when patients were treated with MK-2206 plus erlotinib.
  • There was not a significant improvement in response or disease control rate in the EGFR mutant group.
  • This combination may improve de novo resistance and may be helpful for patients with EGFR wild-type tumors.